Xiangxue Pharmaceutical (300147) — Net Asset Momentum
Xiangxue Pharmaceutical (300147) recorded a net asset momentum of -96.9% as of December 2025, with net assets of CN¥43.95 Million CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See 300147 total equity for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Xiangxue Pharmaceutical Net Asset Momentum (2007–2025)
This chart tracks Xiangxue Pharmaceutical's year-over-year net asset growth across 19 annual reporting periods from 2007 to 2025. The most recent momentum reading is -96.9%, with net assets of CN¥43.95 Million CNY as of December 2025. Check Xiangxue Pharmaceutical (300147) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Asset History for Xiangxue Pharmaceutical (2007–2025)
The table below shows the complete annual net asset history for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see 300147 stock market capitalisation.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | CN¥43.95 Million | CN¥6.75 Billion | CN¥6.70 Billion | ▼ -96.9% |
| 2024 | CN¥1.44 Billion | CN¥7.50 Billion | CN¥6.06 Billion | ▼ -37.8% |
| 2023 | CN¥2.31 Billion | CN¥8.28 Billion | CN¥5.97 Billion | ▼ -17.9% |
| 2022 | CN¥2.82 Billion | CN¥9.35 Billion | CN¥6.53 Billion | ▼ -25.0% |
| 2021 | CN¥3.76 Billion | CN¥11.38 Billion | CN¥7.62 Billion | ▼ -11.6% |
| 2020 | CN¥4.25 Billion | CN¥9.78 Billion | CN¥5.53 Billion | ▲ +3.4% |
| 2019 | CN¥4.11 Billion | CN¥8.46 Billion | CN¥4.35 Billion | ▲ +2.5% |
| 2018 | CN¥4.01 Billion | CN¥8.63 Billion | CN¥4.61 Billion | ▲ +3.3% |
| 2017 | CN¥3.88 Billion | CN¥9.44 Billion | CN¥5.56 Billion | ▲ +5.4% |
| 2016 | CN¥3.68 Billion | CN¥7.99 Billion | CN¥4.30 Billion | ▲ +3.9% |
| 2015 | CN¥3.55 Billion | CN¥4.65 Billion | CN¥1.11 Billion | ▲ +89.5% |
| 2014 | CN¥1.87 Billion | CN¥3.59 Billion | CN¥1.72 Billion | ▲ +9.4% |
| 2013 | CN¥1.71 Billion | CN¥3.47 Billion | CN¥1.76 Billion | ▲ +11.3% |
| 2012 | CN¥1.54 Billion | CN¥2.95 Billion | CN¥1.41 Billion | ▲ +8.3% |
| 2011 | CN¥1.42 Billion | CN¥1.92 Billion | CN¥502.16 Million | ▲ +3.5% |
| 2010 | CN¥1.37 Billion | CN¥1.85 Billion | CN¥476.01 Million | ▲ +306.0% |
| 2009 | CN¥337.62 Million | CN¥698.31 Million | CN¥360.69 Million | ▲ +71.8% |
| 2008 | CN¥196.54 Million | CN¥551.47 Million | CN¥354.94 Million | ▲ +2.7% |
| 2007 | CN¥191.45 Million | CN¥553.43 Million | CN¥361.98 Million | — |